Live Q&A Part 2: Clearing the Way for Better Treatment: Long-Term Relief for Patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
CMEO Webcast
Premiere Date: Tuesday, June 14, 2022This activity offers CE credit for:
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢
Credit Expiration Date: Wednesday, June 14, 2023
Faculty
Joseph K. Han, MD, FARS, FAAAAI (Moderator) Professor Chief, Division of Rhinology & Endoscopic Sinus and Skull Base Surgery Chief, Division of Allergy Eastern Virginia Medical School Norfolk, VA ARS, Immediate Past President AAAAI, RROAC, Chair |
Claire Hopkins, MA, FRCS, DM Consultant ENT Surgeon Guy's Hospital Professor of Rhinology King's College London, UK |
Statement of Need
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a chronic inflammatory disease characterized by rhinosinusitis and the development of polyposis originating in the sinus and eventually extending to the nose. Persistent symptoms include congestion, stuffiness, nasal discharge, facial pain and/or pressure, impairment, or loss of sense of smell, and fatigue. CRSwNP confers a substantial but often underappreciated burden, negatively impacting mental and physical health-related quality of life (HRQoL) endpoints. It is critical that health care professionals (HCPs) understand the burden of CRSwNP, the limitations of traditional therapy, and the potential benefits of biologic therapy on CRSwNP outcomes.
This live Q&A session is your opportunity to ask questions based on the CMEO Snack series that focused on recognizing the burden and impact of CRSwNP, translating the most recent guideline recommendations, and applying up to date safety and efficacy data to make the best treatment decisions for patients.
Learning Objectives
At the end of this CE activity, participants should be able to:
- Recognize the burden of CRSwNP and the impact of this disease on patients' HRQoL and treatment response.
- Translate updated guideline recommendations to treatment decisions for the management of uncontrolled CRSwNP.
- Apply efficacy and safety data to treatment decisions for patients with CRSwNP.
Financial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.
Target Audience
Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in allergy/immunology, and otolaryngology practicing globally
Credit Information
EACCME:
Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Creditâ„¢ toward their credit requirements. CME Outfitters is based in Radnor, Pennsylvania, USA. Please retain certificate as proof of completion.
Dr. Han reports the following financial relationships:
Research Support: AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme
Dr. Hopkins reports the following financial relationships:
Advisory Board: GlaxoSmithKline
Consultant: AstraZeneca and Sanofi Genzyme
Speakers Bureau: Intersect ENT, Inc.; Mylan Pharmaceuticals, Inc.; and Olympus Corporation
The following peer reviewer and CME Outfitters staff have no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
This document was last modified on:
SNQ-162-061422-90